NorthWest Biotherapeutics Inc (NWBO)

[H2R]

Hi Eval,

From different articles and presentations I've read/seen, I would tend to place a historical mPFS around 8 to 10 months. Maybe for some strange reason in this trial it will end up being different, but I would put an 75% chance or more for the placebo group to be close to that range. It would be unlikely IHMO to have the mPFS above, say 12 months. The mPFS will not be confounded by the crossover. So with a placebo mPFS at 12 months (very conservative) assumption (and that's all it is, an assumption), "If mPFS blended for the DCVax-L trial is somewhere between 16.0 to 20 months, " I would see the chances of success to be over 95% on the primary endpoint.

Best.

Good luck to Patients, NWBO, and Longs